Product overview
Incruse Ellipta is used to treat chronic obstructive pulmonary disease (COPD) in adults. Incruse Ellipta exerts its bronchodilatory activity by competitively inhibiting the binding of acetylcholine with muscarinic cholinergic receptors on airway smooth muscle, making it easier for air to get in and out of the lungs. When used regularly, it can help control breathing difficulties and improve health-related quality of life. 1
Reference:
Adverse events should be reported directly to the Health Products Regulatory
Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting side effects you may get.
Incruse and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies